NCT00837876 is a Phase 2 clinical trial of Sorafenib in Pancreatic Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

Who is sponsoring NCT00837876?

NCT00837876 is sponsored by Vanderbilt-Ingram Cancer Center.

What drugs are being tested in NCT00837876?

Interventions in NCT00837876: Sorafenib, Erlotinb.

What condition does NCT00837876 study?

NCT00837876 studies Pancreatic Cancer.

Is NCT00837876 still recruiting?

NCT00837876 is currently completed. Last updated 13 June 2014.

Are results published for NCT00837876?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-06-13 · How we verify

NCT00837876

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial of Sorafenib and Erlotinib in Unresectable Pancreatic Cancer

Completed Phase 2 Results posted Last updated 13 June 2014

What this trial tests

Phase 2 trial testing Sorafenib in Pancreatic Cancer in 37 participants. Completed in 1 November 2012.

Timeline

1 October 2008

Primary endpoint
1 April 2011

1 November 2012

Quick facts

Lead sponsor	Vanderbilt-Ingram Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	1 October 2008
Primary completion	1 April 2011
Estimated completion	1 November 2012
Sites	6 locations across United States

Drugs / interventions tested

Sorafenib (SORAFENIB) — full drug profile →
Erlotinb — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Vanderbilt-Ingram Cancer Center — full company profile →

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Patients With Progression-free Survival
Time frame: at 8 weeks
Number of patients with progression-free survival at 8 weeks

Sponsor's own description

RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with pancreatic cancer that cannot be removed by surgery.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
Krantz BA, O'Reilly EM. · · 2018 · cited 30× · PMID 29269376 · DOI 10.1158/1078-0432.ccr-16-3169
Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma.
Mashayekhi V, Mocellin O, Fens MHAM, Krijger GC, et al · · 2021 · cited 16× · PMID 34522225 · DOI 10.7150/thno.60350
Targeting <i>KRAS</i> in pancreatic adenocarcinoma: Progress in demystifying the holy grail.
Elhariri A, Alhaj A, Ahn D, Sonbol MB, et al · · 2023 · cited 5× · PMID 37700806 · DOI 10.5306/wjco.v14.i8.285

Verify or expand the search:

Other trials of Sorafenib

Trials testing the same drug.

NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT06474663 — A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabi · Phase 1 · withdrawn
NCT06690697 — Combination of Toripalimab and JS004 Therapy for ccRCC · Phase 2 · recruiting
NCT06177496 — Influence of Sarcopenia in Hepatocellular Carcinoma Patients · unknown
NCT05033522 — Immunotherapy for Advanced Liver Cancer · Phase 2, PHASE3 · suspended

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Vanderbilt-Ingram Cancer Center trials

Trials by the same sponsor.

NCT06638398 — Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules · NA · active not recruiting
NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
NCT06105801 — EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing · Phase 4 · recruiting
NCT06399640 — Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia · Phase 1 · recruiting
NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00837876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center
Last refreshed: 13 June 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00837876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing